Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

ATI-450 плюс метотрексат по сравнению с плацебо плюс метотрексат у пациентов с активным ревматоидным артритом от умеренной до тяжелой степени

2 сентября 2026 г. обновлено: Aclaris Therapeutics, Inc.

ATI-450 плюс метотрексат по сравнению с плацебо плюс метотрексат у пациентов с активным РА от умеренной до тяжелой степени, у которых был неадекватный ответ на монотерапию метотрексатом

This study evaluates ATI-450 plus MTX versus placebo plus MTX in participants with moderate to severe active RA who have had an inadequate response to MTX alone.

Обзор исследования

Подробное описание

This is a Phase 2b, randomized, multicenter, double-blind, parallel group, placebo controlled, dose ranging study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of ATI-450 plus MTX versus placebo plus MTX in participants with moderate to severe active RA who have had an inadequate response to MTX alone.

Тип исследования

Интервенционный

Регистрация (Действительный)

251

Фаза

  • Фаза 2

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

      • Pleven, Болгария, 5800
        • Aclaris Investigational Site
      • Plovdiv, Болгария, 4000
        • Aclaris Investigational Site
      • Plovdiv, Болгария, 4001
        • Aclaris Investigational Site
      • Plovdiv, Болгария, 4002
        • Aclaris Investigational Site
      • Plovdiv, Болгария, 4004
        • Aclaris Investigational Site
      • Sofia, Болгария, 1336
        • Aclaris Investigational Site
      • Sofia, Болгария, 1431
        • Aclaris Investigational Site
      • Sofia, Болгария, 1606
        • Aclaris Investigational Site
      • Varna, Болгария, 9000
        • Aclaris Investigational Site
      • Bialystok, Польша, 15-297
        • Aclaris Investigational Site
      • Bialystok, Польша, 15-879
        • Aclaris Investigational Site
      • Dąbrówka, Польша, 62-069
        • Aclaris Investigational Site
      • Krakow, Польша, 30-363
        • Aclaris Investigational Site
      • Lublin, Польша, 20-607
        • Aclaris Investigational Site
      • Nowa Sól, Польша, 67-100
        • Aclaris Investigational Site
      • Poznan, Польша, 60-218
        • Aclaris Investigational Site
      • Poznan, Польша, 60-446
        • Aclaris Investigational Site
      • Poznan, Польша, 61-397
        • Aclaris Investigational Site
      • Sochaczew, Польша, 96-500
        • Aclaris Investigational Site
      • Torun, Польша, 87-100
        • Aclaris Investigational Site
      • Warsaw, Польша, 04-141
        • Aclaris Investigational Site
      • Wroclaw, Польша, 52-442
        • Aclaris Investigational Site
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Польша, 30-002
        • Aclaris Investigational Site
    • Lubelski
      • Tomaszów Lubelski, Lubelski, Польша, 22-600
        • Aclaris Investigational Site
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Польша, 20-362
        • Aclaris Investigational Site
    • Masovian Voivodeship
      • Nadarzyn, Masovian Voivodeship, Польша, 05-830
        • Aclaris Investigational Site
    • Mzowieckie
      • Grodzisk Mazowiecki, Mzowieckie, Польша, 05-825
        • Aclaris Investigational Site
    • Podlaskie Voivodeship
      • Bialystok, Podlaskie Voivodeship, Польша, 15-351
        • Aclaris Investigational Site
    • Silesian Voivodeship
      • Katowice, Silesian Voivodeship, Польша, 40-282
        • Aclaris Investigational Site
    • Warm.Maz.
      • Elblag, Warm.Maz., Польша, 82-300
        • Aclaris Investigational Site
    • Warmińsko-Mazurskien
      • Olsztyn, Warmińsko-Mazurskien, Польша, 10-117
        • Aclaris Investigational Site
    • Wielkopolska
      • Poznan, Wielkopolska, Польша, 61-113
        • Aclaris Investigational Site
    • California
      • El Cajon, California, Соединенные Штаты, 92020
        • Aclaris Investigational Site
      • Encino, California, Соединенные Штаты, 91436
        • Aclaris Investigational Site
      • La Jolla, California, Соединенные Штаты, 92093
        • Aclaris Investigational Site
      • Palm Desert, California, Соединенные Штаты, 92260
        • Aclaris Investigational Site
    • Florida
      • Tampa, Florida, Соединенные Штаты, 33613
        • Aclaris Investigational Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Соединенные Штаты, 73103
        • Aclaris Investigational Site
    • Pennsylvania
      • Duncansville, Pennsylvania, Соединенные Штаты, 16635
        • Aclaris Investigational Site
    • Tennessee
      • Jackson, Tennessee, Соединенные Штаты, 38305
        • Aclaris Investigational Site
    • Texas
      • Cypress, Texas, Соединенные Штаты, 77429
        • Aclaris Investigational Site
      • Mesquite, Texas, Соединенные Штаты, 75150
        • Aclaris Investigational Site
      • San Antonio, Texas, Соединенные Штаты, 78229
        • Aclaris Investigational Site
      • Brno, Чехия, 615 00
        • Aclaris Investigational Site
      • Hlučín, Чехия, 748 01
        • Aclaris Investigational Site
      • Ostrava, Чехия, 702 00
        • Aclaris Investigational Site
      • Pardubice, Чехия, 530 02
        • Aclaris Investigational Site
      • Prague, Чехия, 128 50
        • Aclaris Investigational Site
      • Prague, Чехия, 140 00
        • Aclaris Investigational Site
      • Uherské Hradiště, Чехия, 686 01
        • Aclaris Investigational Site

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 18 лет до 75 лет (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • Able to comprehend and be willing to sign the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved participant ICF prior to administration of any study-related procedures.
  • Diagnosis of adult-onset RA as defined by the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria.
  • Have active moderate to severe RA at Screening.
  • A minimum of 12 weeks on MTX with a stable MTX dose.

Exclusion Criteria:

  • Current acute or chronic immunoinflammatory disease other than RA which may impact the course or assessment of RA.
  • Uncontrolled non-immunoinflammatory disease that may place the participant at increased risk during the study or impact the interpretation of results (eg, previous malignancy, recurrent infection, previous venous thromboembolism).
  • Participant has experience with > 2 biologics, > 1 JAK inhibitor, or a combination of 1 biologic experience and 1 JAK inhibitor.
  • Currently receiving corticosteroids at doses > 10 mg/day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of screening.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Четырехместный

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: ATI-450 20 mg BID plus Methotrexate

ATI-450 20 mg oral tablet twice daily (BID) with a stable weekly dose of methotrexate for 12 weeks

15 mg to 25 mg weekly

Oral, small molecule MK2 inhibitor

Другие имена:
  • зунсеметиниб
Экспериментальный: ATI-450 50 mg BID plus Methotrexate

ATI-450 50 mg oral tablet BID with a stable weekly dose of methotrexate for 12 weeks

15 mg to 25 mg weekly

Oral, small molecule MK2 inhibitor

Другие имена:
  • зунсеметиниб
Плацебо Компаратор: Placebo plus Methotrexate

Placebo oral tablet BID with a stable weekly dose of methotrexate for 12 weeks

15 mg to 25 mg weekly

Placebo tablet manufactured to match ATI-450 in appearance

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Percentage of Participants Achieving ACR20 at Week 12
Временное ограничение: Week 12

Participants achieving American College of Rheumatology (ACR) 20 (responders) were defined as having ≥20% improvement in both the number of swollen and tender joints (66/68 joint counts) and ≥20% improvement in ≥3 of the following 5 measures: Patient's Global Assessment of Disease Activity (VAS), Patient's Assessment of Arthritis Pain (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician's Global Assessment of Disease Activity (VAS), and acute phase reactant as measured by hsCRP.

Model-based estimates and 95% confidence intervals (CIs) were produced.

Week 12

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Концентрации ATI-450 и метаболита (CDD-2164)
Временное ограничение: через 2 часа после приема дозы в дни 1, 8 и 85
через 2 часа после приема дозы в дни 1, 8 и 85
Percentage of Participants Achieving ACR50 at Week 12
Временное ограничение: Week 12

Participant achieving ACR50 (responders) were defined as having ≥50% improvement in both the number of swollen and tender joints (66/68 joint counts) and ≥50% improvement in ≥3 of the following 5 measures: Patient's Global Assessment of Disease Activity (VAS), Patient's Assessment of Arthritis Pain (VAS), HAQ-DI, Physician's Global Assessment of Disease Activity (VAS), Acute phase reactant as measured by hsCRP.

Model-based estimates and 95% CIs were produced.

Week 12
Percentage of Participants Achieving ACR70 at Week 12
Временное ограничение: Week 12

Participants achieving ACR70 (responders) were defined as having ≥70% improvement in both the number of swollen and tender joints (66/68 joint counts) and ≥70% improvement in ≥3 of the following 5 measures: Patient's Global Assessment of Disease Activity (VAS), Patient's Assessment of Arthritis Pain (VAS), HAQ-DI, Physician's Global Assessment of Disease Activity (VAS), Acute phase reactant as measured by hsCRP.

Model-based estimates and 95% CIs were produced.

Week 12
Change From Baseline in DAS28-CRP at Week 12
Временное ограничение: Baseline, Week 12

The DAS28-CRP consists of a composite score of the following variables: TJC28, SJC28, CRP (hsCRP was used for the purposes of this study), and Patient's Global Assessment of Disease Activity. Interpretation of the DAS28-CRP is on a scale of 0 to 9.4, where <2.6 is considered remission, ≥2.6 to <3.2 is considered low/minimal disease activity, ≥3.2 to ≤5.1 is considered moderate disease activity, and >5.1 is considered high/severe disease activity.

The least square (LS) mean change from baseline in DAS28-CRP at Week 12 was estimated from the Mixed Model Repeated Measures (MMRM) model.

Baseline, Week 12
Percentage of Participants Achieving DAS28-CRP Remission (Score <2.6) at Week 12
Временное ограничение: Week 12

The Disease Activity Score using 28 Joint Count-C-reactive protein (DAS28-CRP) consists of a composite score of the following variables: TJC28, SJC28, CRP (hsCRP is used for the purposes of this study), and Patient's Global Assessment of Disease Activity. Interpretation of the DAS28-CRP is on a scale of 0 to 9.4, where <2.6 is considered remission, ≥2.6 to <3.2 is considered low/minimal disease activity, ≥3.2 to ≤5.1 is considered moderate disease activity, and >5.1 is considered high/severe disease activity.

Model-based estimates and 95% CIs were produced.

Week 12
Percentage of Participants Achieving DAS28-CRP Low Disease Activity (Score ≤ 3.2) at Week 12
Временное ограничение: Week 12

The DAS28-CRP consists of a composite score of the following variables: TJC28, SJC28, CRP (hsCRP is used for the purposes of this study), and Patient's Global Assessment of Disease Activity. Interpretation of the DAS28-CRP is on a scale of 0 to 9.4, where <2.6 is considered remission, ≥2.6 to <3.2 is considered low/minimal disease activity, ≥3.2 to ≤5.1 is considered moderate disease activity, and >5.1 is considered high/severe disease activity.

Model-based estimates and 95% CIs were produced.

Week 12
Change From Baseline in HAQ-DI Score at Week12
Временное ограничение: Baseline, Week 12

The HAQ-DI (standard disability method calculation) was utilized to assess the participant's physical function or disability according to the participant. The HAQ-DI is a 20-item, validated questionnaire used to assess the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities [errands and chores]). Responses in each functional area are scored from 0 (no difficulty) to 3 (inability to perform a ask in that area). Overall score was computed as the sum of category scores and divided by the number of categories answered, ranging from 0 to 3. A lower score demonstrated less disability.

LS mean change from baseline in HAQ-DI score at Week 12 was estimated from the MMRM model.

Baseline, Week 12
Change From Baseline in CDAI Score at Week 12
Временное ограничение: Baseline, Week 12

The Clinical Disease Activity Index (CDAI) was the sum of 4 outcome parameters:

  • Tender joint count out of 28 joints (TJC28)
  • Swollen joint count out of 28 joints (SJC28)
  • Patient's Global Assessment of Disease Activity; and
  • Physician's Global Assessment of Disease Activity.

Interpretation of the CDAI disease activity was measured on a scale of 0 to 76, where ≤2.8 was considered remission, >2.8 to ≤10 was considered low/minimal disease activity, >10 to ≤22 was considered moderate disease activity, and >22.0 was considered high/severe disease activity.

LS mean change from baseline in CDAI score at Week 12 was estimated from the MMRM model.

Baseline, Week 12
Percentage of Participants Achieving CDAI Remission (Score ≤ 2.8)
Временное ограничение: Week 12

The CDAI was the sum of 4 outcome parameters:

  • Tender joint count out of 28 joints (TJC28)
  • Swollen joint count out of 28 joints (SJC28)
  • Patient's Global Assessment of Disease Activity; and
  • Physician's Global Assessment of Disease Activity.

Interpretation of the CDAI disease activity was measured on a scale of 0 to 76, where ≤2.8 was considered remission, >2.8 to ≤10 was considered low/minimal disease activity, >10 to ≤22 was considered moderate disease activity, and >22.0 was considered high/severe disease activity.

Model-based estimates and 95% CIs were produced.

Week 12
Percent Change From Baseline in hsCRP Level at Week 12
Временное ограничение: Baseline, Week 12

Blood samples were evaluated to measure levels of hsCRP.

Baseline, Week 12
Change From Baseline in Short Form Health Survey SF-36 Physical Component Summary (PCS) Score at Week 12
Временное ограничение: Baseline, Week 12

The PCS is composed of 4 scales of the Short Form-36 Health Status Survey Questionnaire (SF-36) version 2 assessing physical function, role limitations caused by physical problems, bodily pain, and general health. The range of the SF-36 PCS is between 0 and 100, where higher scores represent better physical functioning.

A 2.5 to 5-point change from baseline is established as the minimum clinically-important difference for the PCS in RA participants.

LS mean change from baseline in SF-36 PCS score at Week 12 was estimated from the MMRM model.

Baseline, Week 12
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue) Score at Week 12
Временное ограничение: Baseline, Week 12

The FACIT-Fatigue is a 13-item questionnaire that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a 4 point Likert scale (4 = not at all fatigued to 0 = very much fatigued). The total score range is from 0 to 52. The higher the score, the lower the fatigue level.

LS mean change from baseline in FACIT-Fatigue score at Week 12 was estimated from the MMRM model.

Baseline, Week 12

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Следователи

  • Директор по исследованиям: Ajay Aggarwal, Aclaris Therapeutics, Inc.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

1 февраля 2022 г.

Первичное завершение (Действительный)

5 сентября 2023 г.

Завершение исследования (Действительный)

11 октября 2023 г.

Даты регистрации исследования

Первый отправленный

18 февраля 2022 г.

Впервые представлено, что соответствует критериям контроля качества

4 марта 2022 г.

Первый опубликованный (Действительный)

15 марта 2022 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

28 сентября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

2 сентября 2026 г.

Последняя проверка

1 сентября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться